Devin King, MD
Ophthalmology · Hurricane, WVNPI 1639192248
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,807 of the $2,836 with a category attached, or 63.7%. Alcon accounts for 62.2% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2024 at $1,591 and has fallen 73.2% since, to $427 in 2025.
Across 49 payments — averaging $57.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- AbbVie$215
- Mallinckrodt Hospital Products Inc.$181
- Sight Sciences, Inc.$131
- Dompe US, Inc.$74
- Carl Zeiss Meditec USA, Inc.$64
- plus $407 from 12 others
What the payments were for
- Travel & lodging$1,01036%
- Food & beverage$1,80764%
- Gifts$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 16 | $1,764 |
| AbbVie(2 entities) | 7 | $215 |
| Mallinckrodt Hospital Products Inc. | 4 | $181 |
| Sight Sciences, Inc. | 3 | $131 |
| Dompe US, Inc. | 3 | $74 |
| Carl Zeiss Meditec USA, Inc. | 1 | $64 |
| Bausch & Lomb Americas Inc. | 2 | $61 |
| Carl Zeiss Meditec, Inc. | 1 | $58 |
| Rxsight Inc | 1 | $47 |
| Thea Pharma Inc. | 2 | $45 |
| Biotissue Holdings Inc. | 2 | $40 |
| Amgen | 1 | $28 |
| Oyster Point Pharma, Inc. | 1 | $27 |
| Novartis | 1 | $25 |
| Harrow Eye, LLC | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Aerie Pharmaceuticals, Inc. | 1 | $18 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LenSx$195
- Clareon PanOptix Pro$125
- PanOptix$102
- ARGOS$100
How this compares
$2,836 in reported general payments places this provider in the 75th percentile of 85 ophthalmology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 106 | $85,443 |
| RocklatanNetarsudil Mesylat/Latanoprost | 69 | $42,528 |
| LumiganBimatoprost | 33 | $17,727 |
| Prednisolone Acetate | 594 | $16,565 |
| RhopressaNetarsudil Mesylate | 30 | $15,747 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 608 | $10,393 |
| Cyclosporine | 23 | $9,008 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 40 | $7,806 |
| Latanoprost | 602 | $5,489 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $5,224 |
| VyzultaLatanoprostene Bunod | 17 | $4,111 |
| TafluprostTafluprost/Pf | 13 | $1,750 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 15 | $1,608 |
| Doxycycline Hyclate | 93 | $1,443 |
| Timolol Maleate | 184 | $1,355 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $215 | $108,394155 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $18 | $58,27599 claims |
| AlconSimbrinza | $1,764 | $7,80640 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $61 | $4,11117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 85 ophthalmology providers in West Virginia.
Other ophthalmology in Hurricane
- Charles FrancisHurricane$2K
- Anthony RealiniMorgantown$410K
- Vishal VermaHuntington$159K
- Joseph SinclairCharleston$9K
- Brian GriffithCharleston$9K
- Stephen CassisMadison$8K
- Jason LudlowCharleston$8K
- Brian McMillanMorgantown$8K
- David GeorgeParkersburg$7K
- Lawrence MinardiCharleston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.